Technical Analysis for STML - Stemline Therapeutics, Inc.

Grade Last Price % Change Price Change
grade F 10.68 4.91% 0.50
STML closed up 4.91 percent on Friday, January 18, 2019, on 1.65 times normal volume. It ran into resistance at its 50 day moving average.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Flat Up
See historical STML trend table...

Date Alert Name Type % Chg
Jan 18 50 DMA Resistance Bearish 0.00%
Jan 18 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
Jan 18 Pocket Pivot Bullish Swing Setup 0.00%
Jan 18 Up 3 Days in a Row Strength 0.00%
Jan 18 Up 4 Days in a Row Strength 0.00%
Jan 17 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 4.91%
Jan 17 Pocket Pivot Bullish Swing Setup 4.91%
Jan 17 Multiple of Ten Bullish Other 4.91%
Jan 17 Inside Day Range Contraction 4.91%
Jan 17 Up 3 Days in a Row Strength 4.91%

Older signals for STML ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Stemline Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing proprietary therapeutics that target cancer stem cells (CSCs) and tumor bulk. It develops StemScreen platform technology consisting of StemScreen-1 and StemScreen-2 for the identification of novel CSC-directed compounds. The company is developing SL-401, a biologic-drug conjugate, which has completed Phase I/II clinical trial for relapsed or refractory acute myeloid leukemia; and SL-701, a synthetic peptide vaccine that has completed two Phase I/II clinical trials for pediatric and adult high-grade gliomas. Its products under preclinical stage include SL-301, a small molecule gamma-secretase inhibitor that inhibits Notch, a pathway expressed by CSCs and tumor bulk of multiple cancer types; SL-101, a mAb-based compound that targets CD123; SL-201, a small molecule active against certain hematologic and solid tumor types; and SL-601, mAb-based compound that targets a cell surface marker on bladder CSCs. The company also in-licensed intellectual property directed to mAb-based therapeutics to validated oncology targets, including Glypican-3, Tie-1, CD133, Frizzled, Smoothened, and Patched. Stemline Therapeutics, Inc. was founded in 2003 and is based in New York, New York.
Is STML a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 2 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 20.55
52 Week Low 7.82
Average Volume 657,535
200-Day Moving Average 15.2746
50-Day Moving Average 10.6854
20-Day Moving Average 9.726
10-Day Moving Average 10.111
Average True Range 0.8032
ADX 16.99
+DI 23.0547
-DI 21.6397
Chandelier Exit (Long, 3 ATRs ) 8.7204
Chandelier Exit (Short, 3 ATRs ) 10.2296
Upper Bollinger Band 11.0961
Lower Bollinger Band 8.3559
Percent B (%b) 0.85
BandWidth 28.173967
MACD Line -0.1363
MACD Signal Line -0.297
MACD Histogram 0.1607
Fundamentals Value
Market Cap 250.5 Million
Num Shares 23.5 Million
EPS -2.47
Price-to-Earnings (P/E) Ratio -4.32
Price-to-Sales 202.21
Price-to-Book 3.03
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 12.02
Resistance 3 (R3) 11.94 11.41 11.79
Resistance 2 (R2) 11.41 11.07 11.45 11.72
Resistance 1 (R1) 11.05 10.86 11.23 11.13 11.64
Pivot Point 10.52 10.52 10.62 10.56 10.52
Support 1 (S1) 10.16 10.18 10.34 10.24 9.72
Support 2 (S2) 9.63 9.97 9.67 9.64
Support 3 (S3) 9.27 9.63 9.57
Support 4 (S4) 9.35